AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16464787 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 12
Study 15210639 — intervention group
Group type: EXPERIMENTAL
Intervention: Video featuring a low SES patient
Number of subjects: 205
Study 15210639 — intervention group
Group type: COMPARATOR
Intervention: Video featuring a high SES patient
Number of subjects: 205
Study 11280530 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 2425
Study 11280530 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 2425
Study 11280530 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 2425
Study 11280530 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole and Omeprazole
Number of subjects: 2425
Study 9815675 — intervention group
Group type: EXPERIMENTAL
Intervention: Central lymphatic irradiation (CLI)
Number of subjects: 20
Study 8508864 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 18
Study 8508864 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 18
Study 3429691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated postmarketing surveillance system
Number of subjects: 2705
Study 3429691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-monitoring request)
Number of subjects: 2705
Study 30513030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-frequency oscillation ventilation (NHFOV)
Number of subjects: 124
Study 30513030 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 124
Study 30830114 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIIIa gene polymorphism (T1565C, rs5918) in Erzya with ischemic stroke
Number of subjects: 248
Study 30830114 — intervention group
Group type: COMPARATOR
Intervention: GPIIIa gene polymorphism (T1565C, rs5918) in healthy Erzya
Number of subjects: 248
Study 30830114 — intervention group
Group type: COMPARATOR
Intervention: eNOS gene polymorphism (G894T, rs1799983) in healthy Erzya
Number of subjects: 248
Study 30830114 — intervention group
Group type: EXPERIMENTAL
Intervention: eNOS gene polymorphism (G894T, rs1799983) in Russian patients with stroke
Number of subjects: 248
Study 27391639 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil Foam (MTF)
Number of subjects: 404
Study 24622243 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 1650
Study 24622243 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 <33.2 ng/mL
Number of subjects: 1650
Study 24622243 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in sST2 for 12 months
Number of subjects: 1650
Study 24622243 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sST2
Number of subjects: 1650
Study 24032185 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal balancing combined with intervention of pathway of qi
Number of subjects: 274
Study 24032185 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture and massage therapy
Number of subjects: 274
Study 20635100 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 120
Study 20635100 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 120
Study 18835318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose recombinant vaccine
Number of subjects: 318
Study 18835318 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose recombinant vaccine
Number of subjects: 318
Study 18835318 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose plasma-derived vaccine
Number of subjects: 318
Study 16983187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 25
Study 15297847 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus oral melphalan (TM group)
Number of subjects: 50
Study 15297847 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide alone (T group)
Number of subjects: 50
Study 11789969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg bid
Number of subjects: 910
Study 11789969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg bid
Number of subjects: 910
Study 11789969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study 9044010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Number of subjects: 70
Study 9044010 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist's clinic
Number of subjects: 70
Study 8345035 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20267 (0.1 mg)
Number of subjects: 12
Study 8345035 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20267 (0.5 mg)
Number of subjects: 12
Study 8345035 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20267 (2.5 mg)
Number of subjects: 12
Study 8345035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3678063 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist consultation in clinic A
Number of subjects: 512
Study 3678063 — intervention group
Group type: COMPARATOR
Intervention: Control group clinic B
Number of subjects: 512
Study 3678063 — intervention group
Group type: COMPARATOR
Intervention: Control group clinic C
Number of subjects: 512
Study 31027435 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPH EROS 18.8 mg under fed conditions
Number of subjects: 30
Study 31027435 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPH EROS 18.8 mg under fasted conditions
Number of subjects: 30
Study 31027435 — intervention group
Group type: COMPARATOR
Intervention: IR MAS 30 mg under fasted conditions
Number of subjects: 30
Study 30824246 — intervention group
Group type: EXPERIMENTAL
Intervention: High homework adherence
Number of subjects: 311
Study 30824246 — intervention group
Group type: COMPARATOR
Intervention: Low homework adherence
Number of subjects: 311
Study 29903095 — intervention group
Group type: EXPERIMENTAL
Intervention: VD supplementation group (800 IU/d for 4 weeks)
Number of subjects: 170
Study 29903095 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor time intervention group (more than 30 min/d for 4 weeks)
Number of subjects: 170
Study 29903095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 170
Study 25250647 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg intravenous, administered 1 hr before and 2 hr after cerebral angiography.
Number of subjects: 160
Study 25250647 — intervention group
Group type: COMPARATOR
Intervention: No NAC (control group).
Number of subjects: 160
Study 23348843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 32
Study 23348843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23348843 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 32
Study 22097196 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 88
Study 22097196 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bazhen Decoction (BZD) in assistant with EN
Number of subjects: 88
Study 22097196 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition
Number of subjects: 88
Study 19165664 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant hCG (Ovitrelle 250 microgr, n = 106)
Number of subjects: 257
Study 19165664 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (triptorelin 0.2 mg, n = 106)
Number of subjects: 257
Study 16621849 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus a forearm support
Number of subjects: 182
Study 16621849 — intervention group
Group type: COMPARATOR
Intervention: Training only
Number of subjects: 182
Study 16621849 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus a trackball
Number of subjects: 182
Study 16621849 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus a forearm support and trackball
Number of subjects: 182
Study 14762743 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reduction and rigid fixation (n = 37)
Number of subjects: 81
Study 14762743 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment without surgical reduction (n = 44)
Number of subjects: 81
Study 14762743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 11846325 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1704
Study 9646621 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg atorvastatin
Number of subjects: 78
Study 9646621 — intervention group
Group type: COMPARATOR
Intervention: 10 mg simvastatin
Number of subjects: 78
Study 9646621 — intervention group
Group type: COMPARATOR
Intervention: 20 mg pravastatin
Number of subjects: 78
Study 9646621 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 78
Study 8195651 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaseron
Number of subjects: 0
Study 2884706 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 0.5 mg
Number of subjects: 18
Study 2884706 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4.0 mg
Number of subjects: 18
Study 2884706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29618476 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 924
Study 26793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine plus aspirin
Number of subjects: 4703
Study 25210447 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity program
Number of subjects: 0
Study 21899803 — intervention group
Group type: EXPERIMENTAL
Intervention: Richly fortified complementary/replacement food
Number of subjects: 743
Study 21899803 — intervention group
Group type: COMPARATOR
Intervention: Basal-fortified complementary/replacement food
Number of subjects: 743
Study 20886790 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp point penetration needling (observation group)
Number of subjects: 66
Study 20886790 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (control group)
Number of subjects: 66
Study 18718423 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating soluble angiotensin-converting enzyme 2 (sACE2) activity
Number of subjects: 0
Study 18718423 — intervention group
Group type: EXPERIMENTAL
Intervention: sACE2 activity
Number of subjects: 0
Study 16450594 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous lidocaine 1 mg/kg
Number of subjects: 200
Study 16450594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200
Study 16450594 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intravenous lidocaine 0.5 mg/kg
Number of subjects: 200
Study 12801256 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole abdominal radiotherapy
Number of subjects: 172
Study 12801256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 172
Study 12801256 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control)
Number of subjects: 172
Study 10569330 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC 2.5 g/day
Number of subjects: 160
Study 10569330 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC 5.0 g/day
Number of subjects: 160
Study 10569330 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC 7.5 g/day
Number of subjects: 160
Study 10569330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 8903534 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 33
Study 8903534 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 33
Study 8903534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 33
Study 1812425 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer membrane vesicle vaccine
Number of subjects: 171800
Study 1812425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171800
Study 1812425 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 171800
Study 6313522 — intervention group
Group type: COMPARATOR
Intervention: twice-daily placebo (n = 77)
Number of subjects: 294
Study 6313522 — intervention group
Group type: EXPERIMENTAL
Intervention: twice-daily captopril 25 mg (n = 77)
Number of subjects: 294
Study 6313522 — intervention group
Group type: EXPERIMENTAL
Intervention: twice-daily captopril 50 mg (n = 71)
Number of subjects: 294
Study 6313522 — intervention group
Group type: EXPERIMENTAL
Intervention: twice-daily captopril 100 mg (n = 69)
Number of subjects: 294
Study 30924570 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (LCD < 100 g carbohydrate/d)
Number of subjects: 14
Study 30924570 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (HCD > 250 g carbohydrate/d)
Number of subjects: 14
Study 30217492 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 850
Study 30217492 — intervention group
Group type: COMPARATOR
Intervention: Nonprotocol therapy
Number of subjects: 850
Study 30217492 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 850
Study 30217492 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab TBP
Number of subjects: 850
Study 27535063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) containing 30μg ethinylestradiol (EE) and 3mg drospirenone (DRSP) in a 21/7 regimen
Number of subjects: 80
Study 27535063 — intervention group
Group type: COMPARATOR
Intervention: Barrier contraceptive method (BCM) or natural family planning method (NFPM)
Number of subjects: 80
Study 24614750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance water filters and improved stoves
Number of subjects: 566
Study 22963592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonblind clinician and patient ratings of treatment response
Number of subjects: 71
Study 22963592 — intervention group
Group type: COMPARATOR
Intervention: Independent evaluators (IEs) ratings using Clinician's Global Impressions‐Improvement Scale (CGI‐I)
Number of subjects: 71
Study 22963592 — intervention group
Group type: COMPARATOR
Intervention: Therapists' ratings
Number of subjects: 71
Study 22963592 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth curve models
Number of subjects: 71
Study 21526664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pretreatment (1 microg/kg diluted in saline to a volume of 5 ml)
Number of subjects: 200
Study 21526664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml normal saline)
Number of subjects: 200
Study 17693179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg, oral, once daily for 6 weeks)
Number of subjects: 89
Study 17693179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, once daily for 6 weeks)
Number of subjects: 89
Study 17693179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin
Number of subjects: 89
Study 17693179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 15599357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp Canal Sealer EWT
Number of subjects: 80
Study 15599357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 80
Study 15599357 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80
Study 15599357 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 80
Study 12907484 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sun exposure when aged 6-15 years (average 2-3 hours or more a day in summer during weekends and holidays)
Number of subjects: 408
Study 12907484 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposure in winter
Number of subjects: 408
Study 12907484 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater actinic damage (grades 4-6 disease)
Number of subjects: 408
Study 12907484 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing sun exposure when aged 6-15 years
Number of subjects: 408
Study 10323379 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH treatment (66 or 100 microg/kg x day s.c. over 2 years)
Number of subjects: 38
Study 10323379 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of GH treatment (66 microg/kg x day s.c.)
Number of subjects: 38
Study 10323379 — intervention group
Group type: EXPERIMENTAL
Intervention: No further GH treatment after initial GH withdrawal (mean adjusted height SD score -2.7, n = 13)
Number of subjects: 38
Study 10323379 — intervention group
Group type: EXPERIMENTAL
Intervention: No further GH treatment after initial GH withdrawal (mean adjusted height -3.3 SD score, n = 9)
Number of subjects: 38
Study 10323379 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 38
Study 8532469 — intervention group
Group type: EXPERIMENTAL
Intervention: One of four randomly assigned intervention strategies
Number of subjects: 100
Study 8532469 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 1752175 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (home made)
Number of subjects: 96
Study 1752175 — intervention group
Group type: COMPARATOR
Intervention: Ludimil (Cida‐Geigy)
Number of subjects: 96
Study 6120705 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of midazolam (Ro 21‐3981, Dormicum) administered p.o.
Number of subjects: 40
Study 6120705 — intervention group
Group type: COMPARATOR
Intervention: 7 mg of oxazepam administered p.o.
Number of subjects: 40
Study 30643079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg dual therapy
Number of subjects: 240
Study 30643079 — intervention group
Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 240
Study 30643079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg dual therapy
Number of subjects: 240
Study 28257326 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization (RSL)
Number of subjects: 409
Study 28257326 — intervention group
Group type: COMPARATOR
Intervention: Wire-guided Localization (WGL)
Number of subjects: 409
Study 26022669 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo)
Number of subjects: 0
Study 25042290 — intervention group
Group type: COMPARATOR
Intervention: US $2.50 food voucher (200 Kenya shillings)
Number of subjects: 1504
Study 25042290 — intervention group
Group type: EXPERIMENTAL
Intervention: US $8.75 food voucher (700 Kenya shillings)
Number of subjects: 1504
Study 25042290 — intervention group
Group type: EXPERIMENTAL
Intervention: US $15.00 food voucher (1200 Kenya shillings)
Number of subjects: 1504
Study 25042290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no compensation)
Number of subjects: 1504
Study 22931971 — intervention group
Group type: EXPERIMENTAL
Intervention: Double kissing (DK) crush
Number of subjects: 75
Study 22931971 — intervention group
Group type: COMPARATOR
Intervention: Provisional side branch (PS) stenting
Number of subjects: 75
Study 22931971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DK and PS groups
Number of subjects: 75
Study 19915080 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 individualized counselor-led MI sessions and nicotine replacement therapy (NRT)
Number of subjects: 122
Study 19915080 — intervention group
Group type: COMPARATOR
Intervention: 4 general health education sessions, self-help materials, and NRT
Number of subjects: 122
Study 17300536 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing session
Number of subjects: 26
Study 17300536 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study 15506574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-tablet computers for data collection
Number of subjects: 168
Study 16325299 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion algorithm
Number of subjects: 60
Study 10579701 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health services (health-oriented services)
Number of subjects: 12
Study 10579701 — intervention group
Group type: COMPARATOR
Intervention: Individual, fragmented, disease-oriented approaches to care
Number of subjects: 12
Study 10579701 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated services aimed at health determinants
Number of subjects: 12
Study 8815557 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electro-stimulation (FES)
Number of subjects: 44
Study 8815557 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal floor rehabilitation with electrostimulation
Number of subjects: 44
Study 1804386 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-leucovorin combination with allopurinol
Number of subjects: 50
Study 1804386 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil-leucovorin combination without allopurinol
Number of subjects: 50
Study 1804386 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders with colon cancer
Number of subjects: 50
Study 6376916 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-g protein-restricted diet supplemented by keto acids
Number of subjects: 0
Study 6376916 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31214846 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step yoga program for T2DM, details on dosage and duration not specified.
Number of subjects: 0
Study 29676600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking while browsing the Internet for vaccination information
Number of subjects: 56
Study 28558000 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training intervention
Number of subjects: 0
Study 28558000 — intervention group
Group type: COMPARATOR
Intervention: Processing speed training active control condition
Number of subjects: 0
Study 28558000 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 0
Study 26776879 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinutren Protect(®) (CP)
Number of subjects: 201
Study 26776879 — intervention group
Group type: COMPARATOR
Intervention: Control isocaloric diet (without TGF-β2 or glutamine)
Number of subjects: 201
Study 25116969 — intervention group
Group type: EXPERIMENTAL
Intervention: Levia® localized NB‐UVB phototherapy
Number of subjects: 21